Paper36780608
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
Ascierto PA and 21 others. J Clin Oncol, 2023. Cited by 150 papers, by iCite.
Cite this record
ConductScience Library. Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. Papers, record 36780608. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36780608
- Disease
- non-small cell lung carcinoma1,066 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
- PubMed
Connected records7
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Diseases7
- non-small cell lung carcinomaOne of its trials lists the paper1,066 drugs, 4,857 trials
- melanomaOne of its trials lists the paper589 drugs, 1,589 trials
- hepatocellular carcinomaOne of its trials lists the paper478 drugs, 1,505 trials
- head and neck squamous cell carcinomaOne of its trials lists the paper424 drugs, 1,056 trials
- gastric cancerOne of its trials lists the paper375 drugs, 1,024 trials
- renal cell carcinomaOne of its trials lists the paper345 drugs, 801 trials
- urinary bladder carcinomaOne of its trials lists the paper159 drugs, 159 trials
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Nivolumab | Major topic |
| Melanoma | Major topic |
| Humans | |
| Antibodies, Monoclonal, Humanized | |
| Antineoplastic Combined Chemotherapy Protocols | |
| B7-H1 Antigen |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P30 CA008748 | NCI NIH HHS | United States | P30CA008748 | PubMed and NIH |
Source NIH RePORTER
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT01968109 | An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT06365619 | Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma | Background | ClinicalTrials.gov |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 36854080 | Combination Immune Checkpoint Inhibition: Is First Line Best? | https://conductscience.org/library/papers/36854080 |
Source PubMed
References11
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33979178 | Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. | J Clin Oncol | 2021 | https://conductscience.org/library/papers/33979178 | PubMed |
| 2 | 31345627 | Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. | Lancet Oncol | 2019 | https://conductscience.org/library/papers/31345627 | PubMed |
| 3 | 35129375 | Treatment patterns and outcomes following disease progression on anti-PD-1 therapies for advanced melanoma. | Future Oncol | 2022 | https://conductscience.org/library/papers/35129375 | PubMed |
| 4 | 29034210 | Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review. | Front Oncol | 2017 | https://conductscience.org/library/papers/29034210 | PubMed |
| 5 | 31562797 | Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31562797 | PubMed |
| 6 | 34710570 | Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy. | Ann Oncol | 2022 | https://conductscience.org/library/papers/34710570 | PubMed |
| 7 | 33989557 | Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. | Lancet Oncol | 2021 | https://conductscience.org/library/papers/33989557 | PubMed |
| 8 | 34986285 | Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. | N Engl J Med | 2022 | https://conductscience.org/library/papers/34986285 | PubMed |
| 9 | 34392069 | The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. | Eur J Cancer | 2021 | https://conductscience.org/library/papers/34392069 | PubMed |
| 10 | 26027431 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26027431 | PubMed |
| 11 | 32463489 | Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma. | Cancer | 2020 | https://conductscience.org/library/papers/32463489 | PubMed |
Cited by108
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 150 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42977756 | Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials. | Nat Med | 2026 | https://conductscience.org/library/papers/42977756 | PubMed |
| 42947736 | Salvage nivolumab plus temozolomide associated with improved survival and clinical benefit in refractory melanoma: a retrospective cohort study. | Front Oncol | 2026 | https://conductscience.org/library/papers/42947736 | PubMed |
| 42891779 | From MAPK Reactivation to Response: Clinical Approaches Targeting BRAF/MEK Resistance in Melanoma. | Am J Clin Dermatol | 2026 | https://conductscience.org/library/papers/42891779 | PubMed |
| 42866251 | Inhibitory receptor profiles for joint prediction of benefit and toxicity in immune checkpoint blockade. | iScience | 2026 | https://conductscience.org/library/papers/42866251 | PubMed |
| 42855599 | LAG3 checkpoint function and its mechanism of action in therapeutic targeting. | Nat Rev Immunol | 2026 | https://conductscience.org/library/papers/42855599 | PubMed |
| 42699247 | Favezelimab plus pembrolizumab for anti-PD-1-refractory classic Hodgkin lymphoma: an open-label phase 1/2 study. | Blood Neoplasia | 2026 | https://conductscience.org/library/papers/42699247 | PubMed |
| 42500571 | Epigenetic Modulators and Immunotherapy in Malignant Melanoma. | Oncol Res | 2026 | https://conductscience.org/library/papers/42500571 | PubMed |
| 42496364 | Accelerating Pediatric Oncology Drug Development: Advances in Clinical Pharmacology, Trial Design, Non-Clinical Evidence, and Regulatory Science. | J Clin Pharmacol | 2026 | https://conductscience.org/library/papers/42496364 | PubMed |
| 42432293 | Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial. | Nat Med | 2026 | https://conductscience.org/library/papers/42432293 | PubMed |
| 42349466 | Updates on intratumoral therapies in melanoma. | Cancer | 2026 | https://conductscience.org/library/papers/42349466 | PubMed |
| 42316819 | Safety of immune checkpoint modulators beyond PD-1/PD-L1 and CTLA-4 in solid tumors: a meta-analysis. | JNCI Cancer Spectr | 2026 | https://conductscience.org/library/papers/42316819 | PubMed |
| 42261754 | Advances in Cancer Immunotherapy for Solid Tumors. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/42261754 | PubMed |
| 42196415 | Plant-Derived Compounds as Potential Sensitizers to Immunotherapy in Melanoma. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42196415 | PubMed |
| 42164864 | Bi-functional anti-LAG-3-IL-2c enhances immune checkpoint inhibitor and CAR T-cell therapy for cancer. | iScience | 2026 | https://conductscience.org/library/papers/42164864 | PubMed |
| 42162306 | Adaptive resistance in cancer immunotherapy. | Cell Mol Immunol | 2026 | https://conductscience.org/library/papers/42162306 | PubMed |
| 42028885 | Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies. | Cancer | 2026 | https://conductscience.org/library/papers/42028885 | PubMed |
| 41928307 | Advances in the treatment of cutaneous tumors: from conventional therapies to targeted and immunotherapeutic strategies. | World J Surg Oncol | 2026 | https://conductscience.org/library/papers/41928307 | PubMed |
| 41886514 | Integrating multimodal management and molecular profiling in a patient with BRAF V600E-positive melanoma and brain metastases. | CA Cancer J Clin | 2026 | https://conductscience.org/library/papers/41886514 | PubMed |
| 41801545 | Melanoma brain metastases outcomes following nivolumab and relatlimab after ipilimumab and nivolumab progression. | J Neurooncol | 2026 | https://conductscience.org/library/papers/41801545 | PubMed |
| 41782961 | Efficacy and Safety of DNV3 (a Lymphocyte-activation Gene 3-blocking Antibody) Combined With Toripalimab and Chemotherapy in Advanced Melanoma: An Open-label, Single-arm Clinical Trial. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/41782961 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BRAF | 673 | PubTator's text mining | https://conductscience.org/library/genes/673 | NCBI Gene |
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CTLA4 | 1493 | PubTator's text mining | https://conductscience.org/library/genes/1493 | NCBI Gene |
| IFNG | 3458 | PubTator's text mining | https://conductscience.org/library/genes/3458 | NCBI Gene |
| LAG3 | 3902 | PubTator's text mining | https://conductscience.org/library/genes/3902 | NCBI Gene |
| MAP2K7 | 5609 | PubTator's text mining | https://conductscience.org/library/genes/5609 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| NIVOLUMAB | CHEMBL2108738 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL2108738 | ChEMBL |
| RELATLIMAB | CHEMBL3990044 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL3990044 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36780608
GET https://conductscience.org/api/papers/v1/36780608/authors?page=2